Focused On-demand Library for Mitochondrial S-adenosylmethionine carrier protein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q70HW3

UPID:

SAMC_HUMAN

Alternative names:

Solute carrier family 25 member 26

Alternative UPACC:

Q70HW3; A8K758; B3KRZ7; F8WAB8; Q7Z786; Q96E68

Background:

The Mitochondrial S-adenosylmethionine carrier protein, also known as Solute carrier family 25 member 26, plays a crucial role in cellular metabolism. It functions as a mitochondrial S-adenosyl-L-methionine/S-adenosyl-L-homocysteine antiporter, facilitating the exchange of vital methyl-group donors and by-products of methylation reactions. This process is essential for the methylation of macromolecules, a key biochemical pathway.

Therapeutic significance:

Linked to Combined oxidative phosphorylation deficiency 28, a mitochondrial disorder with symptoms ranging from metabolic decompensation to developmental delays, the protein's dysfunction underscores its potential as a therapeutic target. Understanding its role could pave the way for innovative treatments for mitochondrial diseases.